Newly-formed company in-licenses LEO Pharma antibiotics

16 May 2018
leo-pharma-big

Denmark's LEO Pharma has done a deal to give UTILITY therapeutics an exclusive license for the antibiotics mecillinam and pivmecillinam.

UTILITY has been created to take on the rights to these drugs, and for the purpose of gaining regulatory approval for them in the USA.

The financial terms of the licence agreement are not being disclosed. UTILITY intends to apply to the US Food and Drug Administration for designation of both mecillinam and pivmecillinam as Qualified Infectious Disease Products for the indication of complicated urinary tract infections.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical